Calamos Advisors LLC Purchases Shares of 30,171 Integra LifeSciences Holdings Corporation $IART

Calamos Advisors LLC purchased a new stake in Integra LifeSciences Holdings Corporation (NASDAQ:IART) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 30,171 shares of the life sciences company’s stock, valued at approximately $284,000.

Several other institutional investors and hedge funds also recently modified their holdings of IART. Fifth Third Bancorp raised its position in Integra LifeSciences by 12,812.9% in the 1st quarter. Fifth Third Bancorp now owns 53,976 shares of the life sciences company’s stock valued at $508,000 after buying an additional 53,558 shares during the last quarter. Sequoia Financial Advisors LLC lifted its stake in Integra LifeSciences by 27.4% in the 1st quarter. Sequoia Financial Advisors LLC now owns 14,233 shares of the life sciences company’s stock valued at $134,000 after acquiring an additional 3,059 shares in the last quarter. Inspire Investing LLC boosted its position in Integra LifeSciences by 46.9% during the 1st quarter. Inspire Investing LLC now owns 55,065 shares of the life sciences company’s stock worth $519,000 after acquiring an additional 17,588 shares during the last quarter. Louisiana State Employees Retirement System acquired a new position in Integra LifeSciences during the 1st quarter worth approximately $280,000. Finally, Hsbc Holdings PLC bought a new position in shares of Integra LifeSciences during the 4th quarter worth approximately $879,000. 84.78% of the stock is owned by institutional investors and hedge funds.

Integra LifeSciences Trading Down 3.0%

NASDAQ IART opened at $19.25 on Friday. The company has a market cap of $1.50 billion, a PE ratio of -2.98, a PEG ratio of 1.33 and a beta of 1.22. The company has a current ratio of 3.38, a quick ratio of 1.95 and a debt-to-equity ratio of 1.75. Integra LifeSciences Holdings Corporation has a 12 month low of $8.70 and a 12 month high of $20.26. The stock has a 50 day moving average of $16.91 and a 200-day moving average of $13.08.

Integra LifeSciences (NASDAQ:IART) last issued its earnings results on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.13. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. The business had revenue of $391.92 million for the quarter, compared to the consensus estimate of $381.81 million. During the same period in the previous year, the company earned $0.41 earnings per share. The firm’s revenue for the quarter was up 2.4% on a year-over-year basis. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. On average, equities research analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.

Analysts Set New Price Targets

IART has been the topic of a number of research reports. Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a research report on Thursday, June 18th. Citigroup reaffirmed a “neutral” rating and issued a $19.00 target price (up from $16.00) on shares of Integra LifeSciences in a research report on Wednesday, July 8th. BMO Capital Markets initiated coverage on shares of Integra LifeSciences in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 price target on the stock. Truist Financial boosted their price target on shares of Integra LifeSciences from $14.00 to $19.00 and gave the stock a “hold” rating in a research report on Thursday. Finally, Weiss Ratings upgraded shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 13th. One research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average price target of $18.33.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.